表观遗传调控及其在肺动脉高压中的治疗潜力

Wang Yu, Yan Lingling, Zhang Ziming, Prado Eric, Fu Linchen, Xu Xuefeng, Du Lizhong

Department of Pediatrics, Children's Hospital of Zhejiang University, Hangzhou, China.

Loma Linda University School of Medicine, Loma Linda, CA, United States.

Front Pharmacol. 2018 Mar 20;9:241. doi: 10.3389/fphar.2018.00241. eCollection 2018.

Recent advances in epigenetics have made a tremendous impact on our knowledge of biological phenomena and the environmental stressors on complex diseases. Understanding the mechanism of epigenetic reprogramming during the occurrence of pulmonary hypertension (PH) is important for advanced studies and clinical therapy. In this article, we review the discovery of novel epigenetic mechanisms associated with PH including DNA methylation, histone modification, and noncoding RNA interference. In addition, we highlight the role of epigenetic mechanisms in adult PAH resulting from undesirable perinatal environments-Extrauterine growth restriction (EUGR) and Intrauterine growth retardation (IUGR). Lastly, we give a comprehensive summary for the remaining challenges and discuss future methods of epigenetic targeted therapy for pulmonary hypertension.

表观遗传学的最新进展对我们理解生物现象以及复杂疾病中的环境应激因素产生了巨大影响。了解肺动脉高压（PH）发生过程中表观遗传重编程的机制对于深入研究和临床治疗至关重要。在本文中，我们综述了与PH相关的新型表观遗传机制的发现，包括DNA甲基化、组蛋白修饰和非编码RNA干扰。此外，我们强调了表观遗传机制在由不良围产期环境——宫外生长受限（EUGR）和宫内生长迟缓（IUGR）导致的成人PAH中的作用。最后，我们全面总结了尚存的挑战，并讨论了未来肺动脉高压表观遗传靶向治疗的方法。